Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Internal medicine (Tokyo, Japan)·2026
Same author

Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.

Case reports in oncological medicine·2026
Same author

Progression of diabetic nephropathy and adverse renal outcomes: possible involvement of Toll-like receptor 4 expression.

Clinical and experimental nephrology·2026
Same author

Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study.

Journal of pharmaceutical health care and sciences·2026
Same author

Development and Clinical Application of a Simultaneous Liquid Chromatography-Tandem Mass Spectrometry Method for Patients with Graft-versus-Host Disease to Quantify the Plasma Concentrations of Ruxolitinib and Posaconazole.

Biological & pharmaceutical bulletin·2026
Same author

Distal renal tubular acidosis triggered by clozapine in a patient with a heterozygous ATP6V0A4 c.1029 + 5G > A variant: a case report and literature review.

BMC nephrology·2025

Related Experiment Video

Updated: May 20, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Delayed decrease in voriconazole concentration after resolution of inflammation in a patient with invasive pulmonary

Haruka Igarashi1, Hayato Yokota2, Ayano Saito3

  • 1Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.

Journal of Pharmaceutical Health Care and Sciences
|May 19, 2026
PubMed
Summary

During active infection, voriconazole (VRCZ) levels may rise. Dose adjustments during inflammation require reassessment post-recovery to maintain therapeutic VRCZ concentrations.

Keywords:
C-reactive proteinCYP2C19Pulmonary aspergillosisTrough plasma concentrationVoriconazole

Related Experiment Videos

Last Updated: May 20, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Voriconazole (VRCZ) is a key antifungal for pulmonary aspergillosis.
  • Active infections can elevate VRCZ levels by reducing cytochrome P450 activity.
  • The effect of VRCZ dose reduction during inflammation on post-inflammation levels is unclear.

Purpose of the Study:

  • To investigate the time-course changes in VRCZ blood concentrations after inflammation resolution.
  • To assess the impact of VRCZ dose reduction during severe inflammation on subsequent VRCZ levels.

Main Methods:

  • Case report of a patient with invasive pulmonary aspergillosis and severe inflammation.
  • Monitoring of VRCZ trough concentrations and C-reactive protein (CRP) levels.
  • Analysis of VRCZ levels following dose reduction during inflammation and after CRP stabilization.

Main Results:

  • High CRP (35.54 mg/dL) correlated with elevated VRCZ (4.7 µg/mL).
  • Dose reduction to 300 mg/day led to decreased VRCZ (1.1 µg/mL) as CRP improved (4.78 mg/dL).
  • Post-inflammation, VRCZ levels dropped to 0.6 µg/mL, necessitating a dose increase to 400 mg/day to reach 1.1 µg/mL.

Conclusions:

  • VRCZ concentrations can fall below therapeutic levels after infection control.
  • Reassessing VRCZ trough levels post-inflammation is crucial after dose reduction during acute illness.
  • This reassessment helps prevent subtherapeutic drug concentrations and ensures effective treatment.